{"url_path":"/sec/arwr/8-k/2026-06-16/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/879407/0000879407-26-000050-index.html","accession_number":"0000879407-26-000050","cik":"0000879407","ticker":"ARWR","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/879407/0000879407-26-000050-index.html","primary_entity_key":"0000879407","primary_entity_name":"ARROWHEAD PHARMACEUTICALS, INC."},"word_count":439,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n(d) Appointment of Dr. Matt Cohen as a Director\n\nOn June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.\n\nDr. Cohen has more than 25 years of experience in healthcare investing and portfolio management, and currently serves as Managing Director at Vida Ventures (“Vida”). Prior to joining Vida in 2025, Dr. Cohen was a portfolio manager and the lead growth-focused healthcare investor at JP Morgan Asset Management (“JPMAM”) since 2005. For almost a decade, he oversaw the portfolio management of growth healthcare assets for industry-leading multi-billion-dollar funds, including his roles as lead portfolio manager of the flagship JP Morgan Global Healthcare Fund and as co-portfolio manager of the JP Morgan Small Cap Growth Fund. For two decades, Dr. Cohen also served as the lead healthcare investor for the JP Morgan Small Cap Growth Fund, the JP Morgan Mid Cap Growth Fund, and the JP Morgan Growth Advantage Fund. In his capacity as portfolio manager and lead sector investor, he led teams of portfolio managers and research analysts focused on performing extensive due diligence and analysis on companies across the healthcare spectrum and market cap range, as part of the team’s fundamental investment process. Before joining JPMAM, Dr. Cohen was a senior analyst at Medici Healthcare (2003-2005) and a senior analyst at Narragansett Asset Management (2000-2003), both New York-based healthcare hedge funds. Prior to that, he was a categorical resident surgeon in the Department of General Surgery at the North Shore University Hospital – NYU School of Medicine.\n\nDr. Cohen holds an M.B.A. from New York University’s Stern School of Business and an M.D. from McGill University in Montreal.\n\nDr. Cohen will receive standard compensation and equity awards available to non-employee directors of the Company. The Company’s non-employee director compensation program is described in the “Director Compensation” section of the Company’s definitive Proxy Statement filed with the SEC on January 27, 2026. In addition, in connection with his appointment, Dr. Cohen will receive a sign-on grant of restricted stock units valued at $887,000. These restricted stock units are scheduled to vest over three years. Dr. Cohen will also enter into the Company’s standard form indemnity agreement.\n\nThere are no family relationships between Dr. Cohen and any of the Company’s directors or executive officers, and there is no arrangement or understanding between Dr. Cohen and any other person pursuant to which Dr. Cohen was appointed as a director of the Company."}